Bupropion and Seizure Threshold
Bupropion lowers the seizure threshold in a dose-dependent manner, with seizure risk of approximately 0.1% at the maximum recommended dose of 300 mg/day for sustained-release formulations and 450 mg/day for extended-release formulations, and is absolutely contraindicated in patients with seizure disorders, eating disorders (bulimia/anorexia), or those abruptly discontinuing alcohol, benzodiazepines, barbiturates, or antiepileptic drugs 1.
Absolute Contraindications
The FDA label explicitly states bupropion is contraindicated in 1:
- Seizure disorder (current or history)
- Bulimia or anorexia nervosa (current or prior diagnosis) - due to higher seizure incidence noted with immediate-release formulation in bulimic patients
- Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs
These contraindications are based on the drug's mechanism of lowering seizure threshold and documented increased risk in these populations 2.
Dose-Dependent Seizure Risk
The seizure risk follows a clear dose-response relationship:
- At ≤300 mg/day (sustained-release): Seizure incidence of 0.06-0.10% in clinical trials 3
- At ≤450 mg/day (extended-release): Cumulative 2-year seizure risk of 0.48% 4
- Above recommended maximum doses: Risk increases substantially 4, 5
The observed seizure rate at therapeutic doses (300 mg/day sustained-release) is comparable to other antidepressants when patients are properly screened 6, 3. However, in smoking cessation trials at 300 mg/day, the incidence is approximately 1/1000 patients 7.
Critical Dosing Limits
Maximum recommended doses 1:
- Extended-release (XL): 450 mg once daily
- Sustained-release: 300 mg/day (typically 150 mg twice daily)
To minimize seizure risk 1:
- Gradually titrate dose upward
- Never exceed maximum daily dose
- Avoid divided doses that exceed single-dose limits
- For extended-release: start 150 mg daily, may increase to 300 mg after 4 days for depression or 1 week for seasonal affective disorder
Predisposing Risk Factors
Over half of reported seizure cases had identifiable predisposing factors 4. Screen carefully for:
- Personal or family history of seizures
- History of head trauma or CNS tumor
- Eating disorders (bulimia, anorexia)
- Concurrent medications that lower seizure threshold 1
- Alcohol or sedative withdrawal states
- Metabolic disorders
- Concurrent use of other medications metabolized by CYP2D6
Special Populations Requiring Dose Reduction
Hepatic impairment 1:
- Moderate to severe: 150 mg every other day
- Mild: Consider reducing dose and/or frequency
Renal impairment 1:
- Consider reducing dose and/or frequency
Clinical Presentation of Bupropion-Induced Seizures
Seizures typically present as 7, 8, 9:
- Generalized tonic-clonic seizures
- Occur within days to weeks of initiation or dose increase
- In overdose: myoclonic seizures progressing to generalized seizures, possible coma with EEG burst-suppression pattern 9
- Can occur even in patients without personal or family seizure history 7, 8
Management Approach
If seizure occurs 1:
- Immediately discontinue bupropion
- Do not rechallenge
- Provide supportive care
Prevention strategy:
- Screen all patients for contraindications before prescribing
- Verify no concurrent medications that lower seizure threshold
- Confirm no active substance use or withdrawal states
- Educate patients about seizure risk and warning signs
- Gradual dose titration per FDA recommendations
Important Caveats
Drug interactions 1:
- Bupropion inhibits CYP2D6, potentially increasing levels of other medications
- CYP2B6 inducers may require dose adjustment (but not exceeding maximum)
- Avoid MAOIs (14-day washout required)
Adolescent use: While the 2025 ATS guideline suggests bupropion for adolescent smoking cessation, the same contraindications and seizure precautions apply 2. The FDA has not approved bupropion for tobacco dependence in patients under 18 years.
Cortical excitability: Bupropion at 300 mg/day has been shown to decrease resting motor threshold on transcranial magnetic stimulation, providing objective evidence of increased cortical excitability 10.